Notizie AIOM – anno XV n. 649
National Survey Reveals Most Americans Are Unaware of Key Cancer Risk Factors
October 24, 2017 - The majority of Americans are unaware of several major risk factors for cancer - most notably obesity, which will soon overtake smoking as the largest preventable cause of cancer in the United States. High treatment costs are compromising care: one in ...Leggi tutto
For Your Patients: ASCO Answers Managing Cancer-Related Pain Booklet
October 25, 2017 - ASCO’s booklet on Managing Cancer-Related Pain helps you work together with your patients to develop an individualized plan for pain management before they start treatment. Patients and their caregivers will learn about the importance of pain relief, ...Leggi tutto
FDA Awards Grants for Clinical Trials to Stimulate Product Development for Rare Diseases
October 25, 2017 - The U.S. Food and Drug Administration (FDA) has awarded numerous new clinical trial research grants, totaling more than $22 million over the next 4 years, to boost the development of products for patients with rare diseases. These new grants were awarded ...Leggi tutto
FDA Accepts sBLA for Bevacizumab in First-Line Ovarian Cancer
October 26, 2017 - The FDA has accepted a supplemental biologics license application (sBLA) for bevacizumab for the first-line treatment of advanced ovarian cancer, according to Genentech, the manufacturer of the angiogenesis inhibitor. If approved, the new indication would ...Leggi tutto
New Biosimilar Educational Materials for Health-Care Professionals From the FDA
October 26, 2017 - The U.S. Food and Drug Administration (FDA) has announced the release of new educational materials for health-care professionals about biosimilar and interchangeable products. The agency developed these educational materials to help increase understanding ...Leggi tutto
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial
There are no data from prospective studies focused exclusively on patients with advanced lung and thymic carcinoids. We aimed to assess the efficacy and safety of long-acting pasireotide and everolimus, administered alone or in combination, in patients with advanced carcinoids ...Leggi tutto
The Revised Declaration of Geneva. A Modern-Day Physician’s Pledge
A newly revised version of the Declaration of Geneva was adopted by the World Medical Association (WMA) General Assembly on October 14, 2017, in Chicago. As the contemporary successor to the 2500-year-old Hippocratic Oath, the Declaration of Geneva, which was adopted by ...Leggi tutto
FDA Approves Intravenous Rolapitant for CINV
October 26, 2017 - The FDA has approved intravenous (IV) rolapitant for use in combination with other antiemetic agents to treat delayed chemotherapy-induced nausea and vomiting (CINV) in adults, according to Tesaro, the manufacturer of the agent. Delayed nausea and vomiting ...Leggi tutto